Powered by

Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update

Registrational Phase 2B Trial Topline Results for Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Expected First Quarter 2017Independent DMC Recommended Continuation of Enrollment of Phase 3 Trial for Imaging Agent 1404Initiated Phase 2/3 Trial of PyL„¢ Imaging AgentIn February 2017, Initiated Phase 1 Trial of PSMA Targeted Therapeutic Candidate 1095Monetized Portion of RELISTOR Royalty Stream through $50 Million TransactionFourth Quarter 2016 RELISTOR (SC and Oral) Net Sales of $16 Millio

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox